Biosynth to Offer Complex Chemistry Solutions at Greater Scales
Biosynth extends its offering to multi-kilogram GMP peptide synthesis through the acquisition of Pepceuticals
STAAD, Switzerland--(BUSINESS WIRE)--Biosynth, a supplier of critical raw materials to the life science industry, is pleased to announce today that it has acquired celares, a leader in the development and manufacture of conjugate vaccines and bioconjugate drugs, activated PEGs, and polymer-based drug delivery excipients.
Biosynth Further Strengthens Peptide Business with Acquisition of Cambridge Research Biochemicals.
STAAD, Germany--(BUSINESS WIRE)--Biosynth Carbosynth (“Biosynth”), a supplier of critical products and services to the life sciences industry, announces today the acquisition of Pepscan, an expert provider of peptide-based products & services.
STAAD, Switzerland--(BUSINESS WIRE)--Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.
OXFORD, England & CAMBRIDGE, England & BOSTON & DUBLIN--(BUSINESS WIRE)--Global molecular diagnostics innovator, Sense Biodetection (Sense), announced today that it had entered into a strategic distribution agreement with Cruinn Diagnostics Ltd. (Cruinn) for the Irish market. Cruinn, a leading supplier in the healthcare and laboratory market, is among the network of planned EU distribution partners authorized to market Veros COVID-19. Sense received CE Mark for Veros COVID-19 in early March 2022.
Biosynth Carbosynth and Jinan Shengquan Group announced their acquisition of Kexing Biopharmaceutical’s raw material factory in Jinan, China. With this acquisition, Biosynth Carbosynth’s and Shengquan’s joint venture Carbotang expands the production capacities significantly. The more than 30,000-square metre property contains a comprehensive factory building on five floors, a demo workshop and a large warehouse including a state-of-the-art dangerous material storage. The expansion, through a further production site, now allows the group more flexibility and larger production volumes together with an increased production reliability. This is an essential prerequisite in the production of Biosynth Carbosynth’s products.
Biosynth Carbosynth, a life sciences reagents and custom synthesis and manufacturing services company, and Jinan Shengquan Group Share-Holding Co., Ltd. have acquired Kexing Biopharmaceutical Co., Ltd’s raw material factory in Jinan, China.